BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.
More here:
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
- Eton Pharmaceuticals Announces Closing of Public Offering [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute... [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Stabilization measures taken [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Coherus BioSciences Announces New Employment Inducement Grants [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Biomerica Reports Fiscal 2021 1st Quarter Financial Results [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- SPACs Show Investors Faster, Simpler Way to Go Public [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Theratechnologies Appoints Two New Board Members [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- First Patient Dosed in Phase II Trial to Treat Complications in COVID-19 [Last Updated On: October 17th, 2020] [Originally Added On: October 17th, 2020]
- Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with... [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Supernus to Host Third Quarter 2020 Financial Results Conference Call [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- CLINUVEL to Trial Innovative Drug in Stroke [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic... [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Transactions in connection with and conclusion of share buyback program [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020 [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020 [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020 [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020 [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed... [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Sanofi: Information concerning the total number of voting rights and shares - September 2020 [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Galapagos’ R&D Roundtable showcases Toledo program [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs) [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress... [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- BioStem Technologies, Inc. Announces Launch of AEON™ [Last Updated On: October 28th, 2020] [Originally Added On: October 28th, 2020]
- electroCore to Present at the 13th Annual LD Micro Main Event Conference [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Tricida to Provide an End-of-Year Business Update [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020 [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021 [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020 [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Signal Relief Patch Reviews – Pain Patch launched - Product Review by Mike Vaughn [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7 [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual... [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a... [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting [Last Updated On: December 7th, 2020] [Originally Added On: December 7th, 2020]
- Avicanna Expands Distribution Network in South America Through Commercial Partnerships in Ecuador and Commercial Export of Feminized Seeds to Uruguay [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Kolab Project Launches 232 Series Limited Edition Live Terpene 510 Vape Cartridges [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Progenity Expands Availability of COVID-19 PCR Testing Services Across United States [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- NextCure Provides Updates on NC318 Clinical Program [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Avenue Therapeutics Provides Regulatory Update for IV Tramadol [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- ALX Oncology Added to the NASDAQ Biotechnology Index [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Publication of Supplementary Prospectus [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Global WholeHealth Partners Corp (OTC: GWHP) Has Paid Off One of Its Outstanding Convertible Notes [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1 [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated... [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development... [Last Updated On: December 17th, 2020] [Originally Added On: December 17th, 2020]
- Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome [Last Updated On: August 5th, 2021] [Originally Added On: August 5th, 2021]
